Top

Published in:

01-02-2020 | Pancreatectomy | Original Article

Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection

Authors: Laura R. Prakash, Huamin Wang, Jun Zhao, Graciela M. Nogueras-Gonzalez, Jordan M. Cloyd, Ching-Wei D. Tzeng, Michael P. Kim, Jeffrey E. Lee, Matthew H. G. Katz

Published in: Journal of Gastrointestinal Surgery | Issue 2/2020

Abstract

Background

Resection of the superior mesenteric and/or portal vein (SMV-PV) is increasingly performed with pancreatectomy for adenocarcinoma. We sought to analyze the impact of cancer at the transected edge(s) of the vein wall.

Methods

Patients who underwent pancreatectomy with vein resection between 2003 and 2015 at a single center were evaluated. R1 resection was defined per guidelines from the American Joint Commission on Cancer and the College of American Pathologists. Specimens were also evaluated for the presence (V+) or absence (V−) of cancer cells at the transected edge(s) and depth of vein invasion.

Results

Among 127 evaluated patients, 114 (90%) received preoperative therapy. R-status was categorized as margin-negative (R0)/V− (n = 72, 57%), R0/V+ (n = 19, 15%), margin-positive (R1)/V− (n = 24, 19%), and R1/V+ (n = 12, 9%). Patients with V− specimens had similar median durations of recurrence-free survival (RFS) (12 vs 9 months) and overall survival (OS) (30 vs 28 months) as did patients with V+ specimens (P > 0.05). In contrast, cancer invasion into the lumen was associated with RFS and OS (P < 0.05). Among patients who underwent R0 resection, V-status had no association with OS, RFS, or local control (P > 0.05).

Conclusion

Cancer invasion into the superior mesenteric and/or portal vein was adversely associated with survival, but cancer at the vein edge(s) was not. Transection of the SMV-PV through macroscopically normal vein may be performed to minimize resected vein length without fear of negatively affecting oncologic outcomes.

Available only for authorised users

Fuhrman GM, Leach SD, Staley CA, Cusack JC, Charnsangavej C, Cleary KR et al. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg. 1996;223(2):154–62.

Tseng JF, Tamm EP, Lee JE, Pisters PW, Evans DB. Venous resection in pancreatic cancer surgery. Best Pract Res Clin Gastroenterol. 2006;20(2):349–64. doi:https://doi.org/10.1016/j.bpg.2005.11.003.CrossRefPubMed

Yekebas EF, Bogoevski D, Cataldegirmen G, Kunze C, Marx A, Vashist YK et al. En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg. 2008;247(2):300–9. doi:https://doi.org/10.1097/SLA.0b013e31815aab22.CrossRefPubMed

Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 2012;36(4):884–91. doi:https://doi.org/10.1007/s00268-012-1461-z.CrossRefPubMed

Ethun CG, Kooby DA. The importance of surgical margins in pancreatic cancer. Journal of surgical oncology. 2016;113(3):283–8. doi:https://doi.org/10.1002/jso.24092.CrossRefPubMed

Amin MB, Edge SB, Greene FL, Compton CC, Gershenwald JE, Brookland RK et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.CrossRef

Kakar S, Shi C, Adsay NV, Fitzgibbons P, Frankel W, Klimstra DS et al. Protocol for the Examination of Specimens From Patients With Carcinoma of the Pancreas. Pancreas Exocrine. Version 4.0.0.1. 2017. http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-pancreas-exocrine-17protocol-4001.pdf. Accessed 15 March 2018.

Abel EJ, Carrasco A, Karam J, Tamboli P, Delacroix S, Vaporciyan AA et al. Positive vascular wall margins have minimal impact on cancer outcomes in patients with non-metastatic renal cell carcinoma (RCC) with tumour thrombus. BJU Int. 2014;114(5):667–73. doi:https://doi.org/10.1111/bju.12515.CrossRefPubMed

Liu NW, Wren JD, Vertosick E, Lee JK, Power NE, Benfante NE et al. The Prognostic Impact of a Positive Vascular Margin on pT3 Clear Cell Renal Cell Carcinoma. J Urol. 2016;195(2):264–9. doi:https://doi.org/10.1016/j.juro.2015.08.099.CrossRefPubMed

10.

Trpkov K, Grignon DJ, Bonsib SM, Amin MB, Billis A, Lopez-Beltran A et al. Handling and staging of renal cell carcinoma: The International Society of Urological Pathology Consensus (ISUP) conference recommendations. American Journal of Surgical Pathology. 2013;37(10):1505–17. doi:https://doi.org/10.1097/PAS.0b013e31829a85d0.CrossRefPubMed

11.

Srigley JR, Zhou M, Allan R, Amin MB, Campbell SC, Chang A et al. Protocol for the examination of specimens from patients with invasive carcinoma of renal tubular origin, 4.0.0.0. 2017. http://www.cap.org/ShowProperty?nodePath=/UCMCon/Contribution%20Folders/WebContent/pdf/cp-kidney-17protocol-4000.pdf. Accessed 29 May 2018.

12.

Hwang RF, Wang H, Lara A, Gomez H, Chang T, Sieffert N et al. Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. Ann Surg Oncol. 2008;15(5):1356–66. doi:https://doi.org/10.1245/s10434-008-9833-1.CrossRefPubMed

13.

Balachandran A, Bhosale PR, Charnsangavej C, Tamm EP. Imaging of pancreatic neoplasms. Surg Oncol Clin N Am. 2014;23(4):751–88. doi:https://doi.org/10.1016/j.soc.2014.07.002.CrossRefPubMed

14.

Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL, Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–7. doi:https://doi.org/10.1001/jama.291.20.2441.CrossRef

15.

Evans DB LJ, Tamm E, Pisters PW. Pancreaticoduodenectomy (Whipple operation) and total pancreatectomy for cancer. In: Fischer JF, editor. Mastery of surgery. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1299–317.

16.

Katz MH, Lee JE, Pisters PW, Skoracki R, Tamm E, Fleming JB. Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques. J Am Coll Surg. 2012;215(2):e11–8. doi:https://doi.org/10.1016/j.jamcollsurg.2012.05.015.CrossRefPubMedPubMedCentral

17.

Katz MH, Fleming JB, Pisters PW, Lee JE, Evans DB. Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg. 2008;248(6):1098–102. doi:https://doi.org/10.1097/SLA.0b013e31818730f0.CrossRefPubMed

18.

Liu L, Katz MH, Lee SM, Fischer LK, Prakash L, Parker N et al. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Am J Surg Pathol. 2015;39(10):1395–403. doi:https://doi.org/10.1097/PAS.0000000000000491.CrossRefPubMed

19.

Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H et al. Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer. 2012;118(15):3801–11. doi:https://doi.org/10.1002/cncr.26717.CrossRefPubMed

20.

Tzeng CW, Fleming JB, Lee JE, Wang X, Pisters PW, Vauthey JN et al. Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy. HPB (Oxford). 2012;14(6):365–72. doi:https://doi.org/10.1111/j.1477-2574.2012.00445.x.CrossRefPubMedPubMedCentral

21.

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations J Am Stat Assoc. 1958;53(282):457–81.CrossRef

22.

Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163–70.PubMed

23.

Kaneoka Y, Yamaguchi A, Isogai M. Portal or superior mesenteric vein resection for pancreatic head adenocarcinoma: prognostic value of the length of venous resection. Surgery. 2009;145(4):417–25. doi:https://doi.org/10.1016/j.surg.2008.12.009.CrossRefPubMed

24.

Snyder RA, Prakash LR, Nogueras-Gonzalez GM, Kim MP, Aloia TA, Vauthey JN et al. Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with thrombosis. Journal of surgical oncology. 2018. doi: https://doi.org/10.1002/jso.25067.CrossRef

25.

Butler JR, Ahmad SA, Katz MH, Cioffi JL, Zyromski NJ. A systematic review of the role of periadventitial dissection of the superior mesenteric artery in affecting margin status after pancreatoduodenectomy for pancreatic adenocarcinoma. HPB (Oxford). 2016;18(4):305–11. doi:https://doi.org/10.1016/j.hpb.2015.11.009.CrossRefPubMedPubMedCentral

26.

Roch AM, House MG, Cioffi J, Ceppa EP, Zyromski NJ, Nakeeb A et al. Significance of Portal Vein Invasion and Extent of Invasion in Patients Undergoing Pancreatoduodenectomy for Pancreatic Adenocarcinoma. J Gastrointest Surg. 2016;20(3):479–87; discussion 87. doi:https://doi.org/10.1007/s11605-015-3005-y.CrossRefPubMed

27.

Boggi U, Del Chiaro M, Croce C, Vistoli F, Signori S, Moretto C et al. Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer. Surgery. 2009;146(5):869–81. doi:https://doi.org/10.1016/j.surg.2009.04.029.CrossRefPubMed

28.

Tran Cao HS, Balachandran A, Wang H, Nogueras-Gonzalez GM, Bailey CE, Lee JE et al. Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer. J Gastrointest Surg. 2014;18(2):269–78; discussion 78. doi:https://doi.org/10.1007/s11605-013-2374-3.CrossRefPubMed

29.

Addeo P, Velten M, Averous G, Faitot F, Nguimpi-Tambou M, Nappo G et al. Prognostic value of venous invasion in resected T3 pancreatic adenocarcinoma: Depth of invasion matters. Surgery. 2017;162(2):264–74. doi:https://doi.org/10.1016/j.surg.2017.03.008.CrossRefPubMed

30.

Khorana AA, Mangu PB, Berlin J, Engebretson A, Hong TS, Maitra A et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34(21):2541–56. doi:https://doi.org/10.1200/JCO.2016.67.5553.CrossRefPubMed

31.

Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G et al. Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg. 2001;5(2):121–30.CrossRef

32.

Raut CP, Tseng JF, Sun CC, Wang H, Wolff RA, Crane CH et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg. 2007;246(1):52–60. doi:https://doi.org/10.1097/01.sla.0000259391.84304.2b.CrossRefPubMedPubMedCentral

33.

Katz MH, Merchant NB, Brower S, Branda M, Posner MC, William Traverso L et al. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2011;18(2):337–44. doi:https://doi.org/10.1245/s10434-010-1282-y.CrossRefPubMed

Title: Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection
Authors: Laura R. Prakash
Huamin Wang
Jun Zhao
Graciela M. Nogueras-Gonzalez
Jordan M. Cloyd
Ching-Wei D. Tzeng
Michael P. Kim
Jeffrey E. Lee
Matthew H. G. Katz
Publication date: 01-02-2020
Publisher: Springer US
Keyword: Pancreatectomy
Published in: Journal of Gastrointestinal Surgery / Issue 2/2020
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-019-04126-y

At a glance: The STEP trials

Springer Medicine

Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

The Water-Holding Procedure for Ensuring Postoperative Continence Prior Restoring Intestinal Continuity

Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC

Clinical Utility of Autologous Salvaged Blood: a Review

Patients with Non-response to Neoadjuvant Chemoradiation for Esophageal Cancer Have No Survival Advantage over Patients Undergoing Primary Esophagectomy

The Prognosis Value of Lymphatic Vessel Invasion in pN0 Gastric Cancer Patients with Insufficient Examined Lymph Nodes

Decreasing Colectomy Rates in Ulcerative Colitis in the Past Decade: Improved Disease Control?